Jin Dachuan, Cui Zhongfeng, Jin Shunqin, Zhou Tao, Guo Baoqiang, Gao Peng, Li Guangming
Department of Liver Disease, Henan Provincial Infectious Disease Hospital, Zhengzhou, China.
Clinical Lab, Henan Provincial Infectious Disease Hospital, Zhengzhou, China.
Front Pharmacol. 2023 Jan 9;13:1096064. doi: 10.3389/fphar.2022.1096064. eCollection 2022.
This study aimed to assess the efficacy of currently used anti-diabetic medications in the treatment of non-alcoholic fatty liver disease (NAFLD) without diabetes.
The efficacy of various anti-diabetic medicines on non-alcoholic fatty liver disease in the absence of diabetes was evaluated by searching Pubmed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCT) only. The methodological quality was evaluated using the Revised Cochrane risk-of-bias tool for randomized trials (RoB2), and the data were analyzed using Stata software (version 15.1).
All papers published between the time of the pooling and September 2022 were searched. There were a total of 18 randomized controlled studies with a total sample size of 1141 cases. The outcomes of interest included variations in alanine transaminase (ALT) and aspartate transaminase (AST). Rosiglitazone (SUCRA: 100%) and vildagliptin (SUCRA: 99.9%) were the best anti-diabetic medicines to improve ALT and AST, respectively, in patients with NAFLD without diabetes, according to the findings of this network meta-analysis.
In accordance with the Network Ranking plot, Rosiglitazone was the best anti-diabetic medicine for improving ALT, and vildagliptin was the best for improving AST in patients with non-diabetic NAFLD.
本研究旨在评估目前使用的抗糖尿病药物在治疗无糖尿病的非酒精性脂肪性肝病（NAFLD）中的疗效。
通过仅在Pubmed、Embase、Cochrane图书馆和科学网中检索随机对照试验（RCT），评估各种抗糖尿病药物在无糖尿病情况下对非酒精性脂肪性肝病的疗效。使用修订后的Cochrane随机试验偏倚风险工具（RoB2）评估方法学质量，并使用Stata软件（版本15.1）分析数据。
检索了汇总时间至2022年9月期间发表的所有论文。共有18项随机对照研究，总样本量为1141例。感兴趣的结果包括丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）的变化。根据该网络荟萃分析的结果，罗格列酮（累积排序曲线下面积：100%）和维格列汀（累积排序曲线下面积：99.9%）分别是改善无糖尿病NAFLD患者ALT和AST的最佳抗糖尿病药物。
根据网络排名图，罗格列酮是改善无糖尿病NAFLD患者ALT的最佳抗糖尿病药物，维格列汀是改善AST的最佳药物。
